Compare ARMP & UXIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARMP | UXIN |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.7M | 226.6M |
| IPO Year | 1996 | 2018 |
| Metric | ARMP | UXIN |
|---|---|---|
| Price | $3.02 | $0.68 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $17.50 | N/A |
| AVG Volume (30 Days) | 75.7K | ★ 98.7K |
| Earning Date | 11-12-2026 | 12-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $59.68 |
| Revenue Next Year | N/A | $71.25 |
| P/E Ratio | ★ N/A | $4.05 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.40 | $0.71 |
| 52 Week High | $14.98 | $4.18 |
| Indicator | ARMP | UXIN |
|---|---|---|
| Relative Strength Index (RSI) | 46.59 | 33.80 |
| Support Level | $2.77 | N/A |
| Resistance Level | $3.96 | $1.02 |
| Average True Range (ATR) | 0.44 | 0.08 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 43.35 | 4.57 |
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
Uxin Ltd is an investment holding company. Along with its subsidiaries, the firm operates a car retailer, pioneering industry transformation with production, new retail experiences, and digital empowerment in China. With its inventory-owning model, it provides customers a comprehensive transaction solution that encompasses the entire value chain, ranging from used-car acquisition, inspection, and reconditioning, warehousing, as well as pre-sales and after-sales services. The group offers high-quality and value-for-money used cars as well as superior full suites of services to customers through a reliable, one-stop, and hassle-free transaction experience. It derives revenues from retail vehicle sales, wholesale vehicle sales, and other businesses. The Group generates its revenues in China.